The JAK2V617F mutation has been shown to promote the onset and development of MPN by increasing the cytokine sensitivity, constitutive activation of JAK2 kinase and the JAK/STAT signaling, and the maintenance of the cytokine-dependent survival in the cell lines [94]. Here, JAK2 is linked to myeloproliferative disorder.